Was haltet Ihr von REPLIGEN? - 500 Beiträge pro Seite

[SuicideKing]

Ich hatte vor einiger Zeit mal positives über Repligen gehört
und habe sie schließlich auch gekauft. Der DWS sollte eigent-
lich auch drin sein, darüber weis ich jedoch nichts konkretes.

Die Aktie hatte sich seit meinem Kauf alles andere als gut
entwickelt. Nach einer heftigen Korrektur sieht es jetzt
allerdings schon wesentlich besser aus. Die Umsätze steigen
und ein neuer Aufwärtstrend wurde geschaffen. Ich bin nun am
überlegen, ob man eventuell schon nachkaufen sollte oder viel-
leicht noch ein paar news abwarten sollte.

Würde mich sehr freuen, wenn Ihr hier ein paar Meinungen
preisgeben würdet.

[erkilein]

RGEN entwickelt ein medikament gegen Autismus. Diese Krankheit ist doppelt so hoch verbreitet wie MS. Die traials befinden sich in phase II. lt.homepage repligen.com gibt es zzt. keinerlei medikamente gegen diese krankheit, so dass man ein first mover wäre. kann das jemand bestätigen? mit was behandelt man denn solche patienten im augenblick? Puhvogel?

[puhvogel]

Woher weisst Du denn schon wieder, dass ich die auch habe.
Mir gefällt einfach die Geschichte, obwohl die Proteinverkäufe im letzten Quartal leider stark zurückgegangen sind. Ich bin aber bzgl Autismus völlig unbedarft, meine "Kenntnisse" beruhen vorwiegend auch nur auf "Rain man".
Die Prävalenz von MS und Autismus ist angeblich gleich: 10 auf 100000. Die Diagnose von Autismus ist aber sicher eine sehr schwammige Sache.
Autismus kann eine schwere Krankheit mit großem volkswirtschaftlichen Schaden sein, betrifft Kinder und wird offenbar bisher nicht gezielt medikamentös behandelt, sondern mit der in der Psychatrie üblichen Schlaghammermethode (Serotonin-Antagonisten).
http://www.m-ww.de/krankheiten/psychische_krankheiten/autism…
Bei einer solchen Story denke ich dann auch sofort an die Biogen-story. Teuer sind ist RGEN gewiss nicht.

Du hast im Yahoo-Board rechechiert, oder? Der drbio ist in der Tat kein Pusher und ich verwende ihn gerne als Tipgeber.
Habe auch heute seine ESPR angeschaut, auch eine nette Story, aber da möchte ich erst mal Phase 2 Daten sehen. Der Markt ist aber gross.

Im Fall Decode habe ich gestern das erste mal in meinem Leben über einen Kauf eines Genomicswerts nachgedacht. Eigentlich stehen Fondmanger auf solche Nachrichten (Kooperation mit einer Pharmafirma), auch wenn es langfristig eher geschäftschädigend sein kann. Roche hat aber bei weitem nicht das Gewicht einer Pfizer oder einer Glaxo.

Vielleicht sollte wir mal einen neuen Thread aufmachen, unter dem Motto "vermögenden Mauerblümchen". Also ein Sammelthread für Werte die eine lange Abwärtsbewegung hinter sich haben, aber noch genügend Cash (Minimum 20 Millionen) für 5 Jahre Forschung (bezogen auf die aktuelle Burn-rate) haben oder die ohne weitere Geldzuschüsse eines ihrer Medikament noch zur Genehmigung bei der FDA vorlegen können, sofern die zugehörigen Studien nicht platzen.
Zumindestens sollten die Cash-Bestände aber die Hälfte der
Der Thread sollte aber aber frei von tiefergegehenden fundamentalen Betrachtungen bleiben, wie Pipeline, Analystenschätzungen oder gar Mäusedaten .

Schema: 2 Charts, Marktkapitalisierung, Bargeldbestände minus Schulden, und wenn vorhanden, den Grund für die schlechte Performance.

Was meinste?

[erkilein]

das sind genau die daten, nach denen ich meine käufe mache...wäre o.k.
RGEN hab ich seit 2 monaten auf der wl, heute früh noch mal fix geschaut und wirklich dbio oder wie er sich nannte, seine kaufargumente durchforsett und abgeglichen, leider hatte ich zuwenig cash um in berlin zu 3 mir richtig den sack vollzuladen, mußte erst meine russen nach hause schicken (vimpel) und dann hamse mir nischt mehr gegäbm

vlgc fliegt wieder

[t.1]

Nach Ansicht der Gesellschaft Autism von Amerika, leiden 1 mindestens auf 500 (oder 500.000) Amerikaner unter irgendeinem Formular von autism.

Resultate von den klinischen Versuchen der Phase 2 Repligen werden früh in 2001 erwartet.

Es gibt aktuell keine FDA-approvedbehandlungen für diese debilitating Störung.

Ausgedehntes US-Patent herausgab zu Repligen für den Gebrauch Secretin als Behandlung für autism.


Das Vorherrschen von autism ist grösser als Brustkrebs, cerebal Lähmung, und die cystic kombinierte Fibrosis.


besser ist aber die zweite forschung von repligen die sich auf knochenmarktransplantation beschäftigt.dann würde es föllig egal sein von wem die spende kommt. keine suche mehr nach geeigneten spendern.
grüße t.1

[erkilein]

auch mit an bord?
erst dachte ich, mein freund t1 ist ausländer...aber dann fiel mir doch das Übersetzungsprogramm ein...

longplay: NZYM
aufpassen bei BLSI, da kommt was gewaltiges
sowie SGEN techn.

[puhvogel]

@t1: Du hast recht. Ich habe einfach eine Null vergessen. Die Prävalenz sowohl bei MS als auch bei Autimus ist in etwa 100 auf 100000 Einwohner.
http://oitcourses.sfasu.edu/spe329/unitslides/Chap10slides/s…
Ist sicher auch Auslegungssache, was man zu Autismus zählt und was nicht. MS kann man einfach anhand der Entzündungsherde durch ein Kernspinaufnahme feststellen.

[t.1]

@erkilein
@puhvogel
bin nur mit kleiner anzahl drin ,denke mit der zeit billiger ranzukommen.was für die aktie spricht ist einfach drei produkte in phase 2 in einem breitem markt wo geld zu verdienen ist . alle drei produkte liegen bis jetzt erfolreich im rennen.das gibt zeit zum einkauf.

[erkilein]

wohin willst Du? 3,50-5 oder mehr?

[puhvogel]

Nachrichten abwarten.
Mit 3.5$ gebe ich mich gewiss nicht zufrieden.

[erkilein]

Was ist davon zu halten,puhvogel? bei 51 % der Kinder wurden Wirkungen erzeugt in Phase II, nicht berauschend oder?

Friday July 20, 9:06 am Eastern Time
Press Release
SOURCE: Repligen Corporation
Secretin Clinical Data Presented at Autism Society of America Annual Meeting
Meta-Analysis of Four Phase 1 Studies Shows Statistically Significant Treatment Effect
NEEDHAM, Mass., July 20 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) today presented data from its Phase 2 clinical trial of secretin in autism at the annual meeting of the Autism Society of America in San Diego. The data showed that patients treated with secretin had an improvement in symptoms over the eight-week period of the trial using multiple types of assessments, which was particularly evident in a subgroup of patients defined by two biomarkers. The Company also presented a meta-analysis of four previously published Phase 1 studies involving smaller numbers of patients and fewer doses of secretin. In the four Phase 1 studies, clinical ``responders`` were defined with a Clinical Global Impression of improvement, the Preschool Language Scale, parental reports of improvement and the Childhood Autism Rating Scale respectively. In the meta analysis, responder data from the four studies was pooled to assess the rate of clinical response to secretin compared to a placebo. The outcome of this analysis showed a greater number of patients with a clinical response to secretin compared to placebo, a difference which was statistically significant (p=0.02).

``The pooled data from these four Phase 1 studies provide evidence of a secretin treatment effect,`` stated Walter Herlihy, President and CEO of Repligen. ``This result is remarkable given the preliminary nature of these Phase 1 studies including short duration, limited dosing, heterogeneous patient populations and the use of assessment tools which were designed solely for the diagnosis of autism.``

The results from Repligen`s Phase 2 clinical trial demonstrated a significant treatment effect of secretin in the entire patient population using the parental Clinical Global Impression scale (p=0.02). Further analysis defined two biomarkers for which 51% of the patient population had values in the normal range. In this subgroup of 64 patients, there was a statistically significant effect of secretin by four endpoints including social function as determined with the Autism Diagnostic Observation Schedule (p=0.016), and the Clinical Global Impression Scale (``CGI``) as determined by a professional (p=0.02) and independently by a parent (p<0.001).

The Company also presented new data from the Phase 2 trial on a fourth endpoint, language development as determined by the MacArthur Communicative Development Inventory. The MacArthur language scale assesses the numbers of words used and the number of words understood in children with minimal language capabilities. It is based on an assessment of a child`s use and understanding of a defined vocabulary of 396 words. In the subgroup of 64 patients defined with the biomarkers, secretin-treated patients had an average increase in receptive language of 33 words compared to a 6 word increase in the placebo group, a difference which was statistically significant (p=0.02).

Meta-Analysis of Clinical Response

The four published placebo-controlled Phase 1 studies enrolled a heterogeneous patient population with a wide range of age, function level and GI symptoms. Each study used different assessment tools to evaluate the patients` response to secretin. The meta-analysis was carried out to determine if secretin-treated patients had a higher response rate than placebo-treated patients as determined with one of the assessments carried out in these studies. The definition of a ``responder`` included: 1. a Clinical Global Impression of change of ``very much improved`` or ``much improved`` for at least one symptom in 2 of 5 clinical visits (Sandler, A., et al, New Eng. J. Med., 1999, 341:1801), 2. an improvement on the Preschool Language Scale of at least 4 points (Dunn-Geier, J., et al, Dev. Med. Child Neurol., 2000, 42:796), 3. improvements in multiple symptom domains as reported by parents (Roberts, W., et al, Pediatrics, 2001, 107(5):E71) and 4. a clinically significant improvement on the Childhood Autism Rating Scale (more than 4.09 points; Coniglio, S., et al, J. Pediatrics., 2001, 138:649). In all four studies there was a higher percentage of clinical responders in the secretin-treated group than in the placebo group although the difference was not statistically significant in any one study due to the number of patients evaluated and the variability inherent in the measurements. However, when the four studies are pooled together, there is a 29% clinical response rate in the four secretin- treated groups vs. a 16% clinical response rate in the placebo groups, a difference that is statistically significant (p=0.02). Thus, a secretin treatment effect is evident in these Phase 1 studies despite the inherent limitations in assessing behavioral changes in short-term trials in a heterogeneous patient population.

Phase 2 Clinical Trial

Repligen`s Phase 2 clinical trial evaluated three doses of secretin or a placebo in 126 children, 3 to 6 years of age, with moderate to severe symptoms of autism and reported gastrointestinal symptoms. A stool sample was collected from each patient at the beginning of the trial and subsequently analyzed for two proteins: calprotectin, a marker of gastrointestinal inflammation and chymotrypsin, an enzyme released from the pancreas during digestion. For each protein, 25-30% of the patients had an abnormal value prior to treatment with secretin or a placebo. The ability to demonstrate a secretin-related treatment effect was dramatically improved in the 64 patients, or 51% of the total patient population, with normal levels of both proteins. The clinical trial was carried out at the Southwest Autism Research Center/Phoenix Children`s Hospital (Phoenix, AZ), the Rochester Institute for Digestive Diseases and Sciences (Rochester, NY), the University of Maryland Medical Center (Baltimore, MD), the Mayo Clinic (Rochester, MN) and the MIND Institute/University of California, Davis (Sacramento, CA).

Repligen Corporation develops new drugs for debilitating pediatric diseases including autism, cancer, and immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com.

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance, management`s plans and objectives for future operations, product plans and performance, management`s assessment of market factors, as well as statements regarding the strategy and plans of the company and its strategic partners, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward- looking statements, including, without limitation, risks associated with the following: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed and more mature pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Authority regulations, our ability to obtain and maintain intellectual property rights for our products and processes, the risk of litigation regarding our intellectual property rights, our limited sales and marketing experience and capabilities, our limited manufacturing capabilities, our dependence on third-party manufacturers, our ability to hire and retain skilled technical and scientific personnel, our volatile stock price, and other risks detailed in the company`s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

SOURCE: Repligen Corporation

[puhvogel]

Nee erkilein, da machst Du dir es zu einfach.
Wenn keine medikametöse Therapie existiert, dann ist einfach jeder Fortschritt zulasssungsverdächtig. Immerhin kloppen sich die Anleger um IMCL, weil die bei 22,5% der Krebspatienten eine signifikante Antwort festgestellt wurde.

[t.1]

puhvogel hat in diesem punkt recht, da es keine therapieansätze für diese erkrankung gibt.es wird sehr genau hingesehen wenn erfolge sichtbar werden.HIV und leichte besserung oder eindämmung lassen kurse explodieren.aber immer nur dann, wenn keine mittel zur heilung auf dem markt sind.(siehe viagra...)
grüße t.1

[erkilein]

na denn...Wer hat eigentlich bei parkinson und alzheimer die nase vorn oder bei der häufigsten todesursache,herzversagen?

[puhvogel]

Bei Parkinson finde ich noch nichts pralles.
Bei Alzheimer könnte dies ein Durchbruch werden:

RPT-Elan, AHP in phase 2 Alzheimer`s drug trial
DUBLIN, July 23 (Reuters) - Irish pharmaceuticals company Elan Corp (quote from Yahoo! UK & Ireland: ELN.L)(NYSE:ELN - news) and U.S. drug firm American Home Products Corp on Monday said they planned to begin phase two trials of an experimental vaccine("Impfung") for Alzheimer`s disease.

``Elan and AHP plan to initiate a multicentre exploratory phase 2A clinical study with approxiamately 375 patients with mild to moderate Alzheimer`s disease at sites in the U.S. and Europe,`` said the two companies in a joint statement.

The study, which will commence in the third quarter of 2001 and last approximately two years, follows the completion of phase one safety trials of the drug, known as AN-1792 or AIP-001, with more than 100 Alzheimer`s patients.

Leider nur große Firmen (Elan ist mittlerweile doppelt so groß wie Schering)

[erkilein]

das ist das problem...aber wenn ich bedenke, wo die überall ihre finger drin haben...hmm...konservativer wachstumswert.

[erkilein]

was ist eigentlich mit BLSI und altropane für parkinson?

[puhvogel]

Altropane ist nur für die Diagnose, für junge Leute wie den M.J Fox.
Das wird ganz schwer zu verkaufen.

[erkilein]

Repligen Reports First Quarter 2002 Results
Company Updates Progress on Product Development Programs

NEEDHAM, Mass., Aug 10, 2001 /PRNewswire via COMTEX/ -- Repligen Corporation (Nasdaq: RGEN chart, msgs) today reported results for the first quarter of fiscal 2002, which ended June 30, 2001. Revenues for the quarter of $713,000 consisted entirely of sales of Protein A products. Sales increased 28% over Q1 of fiscal 2001 to the highest level recorded to date. Total revenues were $661,000 for the same period in fiscal 2001. Expenses for the quarter increased 12% to $2,400,000 from $2,144,000 in fiscal 2001 due to increased development costs associated with proprietary drug development programs. The net loss for the quarter was $1,343,000 or $.05 per share, compared to a net loss of $970,000 or $.04 per share for the quarter ended June 30, 2000. Cash and investments as of June 30, 2001 were $28,101,000.

"During the quarter we achieved record product sales and maintained a low `burn rate` relative to our cash position" stated Walter C. Herlihy, President and CEO of Repligen. "Our strong financial position will enable us to aggressively pursue expanded development efforts for our three therapeutic product candidates in the coming year."

Update on Product Development Programs


Secretin for Autism

During the quarter, we completed the analysis of our Phase 2 clinical trial of secretin for autism. The Phase 2 trial evaluated three doses of secretin or a placebo in 126 children, 3 to 6 years of age, with moderate to severe symptoms of autism and reported gastrointestinal symptoms. A stool sample was collected from each patient at the beginning of the trial and subsequently analyzed for two proteins: calprotectin, a marker of gastrointestinal inflammation or colitis and chymotrypsin, an enzyme released from the pancreas during digestion. For each protein, 25-30% of the patients had an abnormal value prior to treatment with secretin or a placebo.

A statistically significant treatment effect of secretin was demonstrated in the 64 patients, or 51% of the total patient population, with normal levels of both proteins. In this subgroup, there was a statistically significant effect of secretin by four endpoints including improvement in social function as determined with the Autism Diagnostic Observation Schedule (p=0.016), overall symptom changes as determined by the Clinical Global Impression Scale ("CGI") by both a professional (p=0.02) and independently a parent (p<0.001) and an increase in receptive language as determined by the MacArthur Communicative Development Inventory (p=0.02). We have communicated these data to the FDA as the basis for a discussion of the next step in the development of secretin for autism.

During the quarter, we also completed the first in a series of experiments to evaluate the neurological activity of secretin in animal models. Insights gained from these experiments may suggest a mechanism of action of secretin in autism. We intend to present our initial findings at the Society of Neuroscience meeting in San Diego in November.

Uridine for Mitochondrial Disease

Mitochondria are structures essential for many cellular functions, including energy production and are the only non-dietary source of uridine, an essential component for the production of RNA and DNA. Forms of mitochondrial disease affect approximately 20,000 people in the United States and result in symptoms including seizures, skeletal and cardiac muscle weakness and neurological and cognitive defects. We are developing a form of uridine for the treatment of mitochondrial disease in collaboration with the University of California, San Diego, Mitochondrial and Metabolic Disease Center. During the quarter we made significant progress on the development of a manufacturing process and a formulation of uridine for clinical studies. Investigators at UCSD are developing a clinical protocol for a placebo-controlled Phase 2 clinical trial of uridine in mitochondrial patients which they intend to submit to the FDA later this year.

CTLA4-Ig for Stem Cell Transplantation

We are currently carrying out a Phase 2 clinical trial of our CTLA4-Ig in patients receiving a stem cell transplant (SCT) for leukemia and other related diseases. This study will seek to extend and confirm the observation from Phase 1 studies that pre-treatment of the transplant with CTLA4-Ig can prevent the development of Graft vs. Host Disease ("GVHD" or rejection) in patients receiving a SCT from a "genetically mismatched" donor. During the quarter we also continued to manufacture CTLA4-Ig to support clinical trials for additional clinical indications which we intend to initiate later this year.

SecreFlo(TM) for Pancreatic Diagnosis

In November 2000, we announced that the FDA had issued an "approvable letter" for the use of synthetic porcine secretin (SecreFlo(TM)) for the diagnostic assessment of pancreatic function. The "approvable letter" indicated that SecreFlo(TM) could be approved, pending a satisfactory response to a series of additional questions concerning the manufacture and quality control of the product. During the quarter our partner, ChiRhoClin, manufactured an additional lot of product produced at a second site to confirm that it meets all quality control criteria. These data will be submitted to the FDA as part of ChiRhoClin`s response to the questions raised by the FDA.

Repligen Corporation develops new drugs for debilitating pediatric disorders including autism, cancer, and immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com.


SELECTED FINANCIAL DATA

Operating Statement Data:
Three-Months Ended
June 30,
2001 2000
Revenues:
Product $713,000 $556,000
Research -- 30,000
Other -- 75,000
Total revenues 713,000 661,000

Costs and expenses:
Research and development 1,427,000 1,083,000
Selling, general and administrative 617,000 731,000
Cost of products sold 356,000 330,000
Total costs and expenses 2,400,000 2,144,000

Loss from operations (1,687,000) (1,483,000)

Investment and interest income 344,000 513,000

Net loss $(1,343,000) $(970,000)

Net loss per common share outstanding $(.05) $(.04)

Weighted average common shares outstanding 26,633,000 26,456,000


Balance Sheet Data:
June 30, 2001 March 31, 2001

Cash and investments $28,101,000 $29,929,000


Total Assets 30,673,000 32,148,000


Stockholders` equity 29,550,000 30,891,000

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance, management`s strategy, plans and objectives for future operations and product plans and performance, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in the company`s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X26384772



Source: Repligen Corporation

[puhvogel]

Keine echte Überraschung, finde ich:
Repligen says has FDA Fast Track for autism drug
NEEDHAM, Mass., Sept 5 (Reuters) - Repligen Corp. (NasdaqNM:RGEN - news) said on Wednesday that the U.S. Food and Drug Administration has granted Fast Track designation for its secretin drug used in the treatment of pediatric autism.
Under FDA rules, a Fast Track designation means a product will be reviewed in an expeditious manner if the drug is intended for the treatment of a serious or life-threatening condition and it demonstrates the potential to address unmet medical needs for such a condition.
Autism is a serious developmental disorder characterized by defects in socialization, communication and repetitive behaviors, which afflicts 500,000 people in the United States.
``We are very pleased that the FDA has designated this program for Fast Track status,`` stated Walter C. Herlihy, President and Chief Executive Officer.

[erkilein]

dem kurs scheint es aber gut zu tun, hoff mer mal auf ein pendeln zw. 2-3 $. in dieser zeit sollte man zufrieden sein, wenn die eigenen aktien nicht in den pennybereich fallen...sollte also die nasd noch bis 1100 runterpurzeln bestehen echte chancen, dass 2 $ halten...

[erkilein]

die 2 haben gehalten. RGEN verlässt die Flagge Richtung 3 $.

[erkilein]

so schnell sind es 100 %, hat heute die 4 $-Marke übersprungen, da stehen pos. resultate für die klinischen Tests an

[erkilein]

damit man auch sieht, dass heute 4,50 $ angekratzt wurden und der langfristige Chart auch technisch sich zusehends bessert:

[puhvogel]

Hmmm. Demnächst läuft meine 1-Jahres-Haltefrist aus. Eigentlich steigt die Aktie ohne offensichtlichen Grund und ohne unmittelbar anstehende Daten (so weit ich es weiss).
Das wir uns ohne gute News auf die alten Höhen schwingen können, das möchte ich doch bezweifeln, wo es den Rest der Bios nicht so geht.
Ich wusste übrigens gar nicht, dass RGEN so ein Bio-Opi ist.

[erkilein]

wann läuft deine haltefrist aus? meine im juli. aber so etwas interessiert mich eigentlich nicht. nur kann man beim kurzfristigen mitnehmen der gewinne auch einen knaller verpassen...vielleicht ist der anstieg auch nur mit zukünftigen guten forschungsdaten begründbar oder rein technisch? ich weiss es nicht. ich neige aber fasst dazu, abzugeben. in diesem jahr werden viele aktien 30-50 % hoch und wieder runter gehen, grosser sägezahnmarkt.

[puhvogel]

Ich meine im Juni. Schade, das war ein guter Austiegszeitpunkt.
Ein Manager hat übrigens eigene Aktien gekauft.

[erkilein]

was denkst du zu LYNX? am montag 01.04. 1 pm gibts zahlen, ich bin mir da nicht ganz sicher, was wird. zuletzt war die news, dass lynx bei celera in die datenbank integriert worden sei. hoffentlich können die ihre cashposition ausbauen...das handelsvolumen lässt nichts gutes erahnen ab montag, hab reichlich zu 2,30...

[erkilein]

Friday April 5, 11:06 am Eastern Time
FDA Approves RepliGen`s Synthetic Gut Hormone Secreflo
By: Otesa Middleton

Dow Jones Newswires

WASHINGTON -- The Food and Drug Administration approved SecreFlo Friday as the first synthetic secretin, a gut hormone used to diagnose pancreatic dysfunction and tumors.

Cangene Corp.`s subsidiary Chesapeake Biological Laboratories manufactures SecreFlo for RepliGen Corp. (RGEN). SecreFlo, an injection, mimics the pig form of the hormone.

After SecreFlo is used, pancreatic secretions are measured to determine if there are tumors, called gastrinoma, or other problems obstructing the organ.

In a poorly functioning pancreas, a thick mucus covers the pancreas, blocking enzymes that break down food. This leaves patients malnourished and dehydrated because of improperly digested food.

RepliGen is also studying secretin for autism in children.

-By Otesa Middleton, Dow Jones Newswires; 202-862-6654; Otesa.Middleton@ dowjones.com

[erkilein]

Tuesday May 28, 10:54 am Eastern Time
Repligen`s Files NDA For SecreFlo In ERCP

WALTHAM, Mass. -(Dow Jones)- Repligen Corp. filed a supplemental New Drug Application with the Food and Drug Administration for SecreFlo, a synthetic porcine secretin, that broadens the product`s diagnostic range.

In a press release Tuesday, the company said the clinical data submitted in the sNDA supports the use of SecreFlo in patients undergoing ERCP, a type of invasive X-ray imaging procedure. The secretin, derived from pigs, helps locate and open the minor pancreatic ducts in patients with pancreas divisum, a disorder that causes unusually small ducts.

Endoscopic retrograde cholangiopancreatography, referred to as ERCP, is a procedure that allows doctors to diagnose and treat disorders of the gallbladder and pancreas.

A multicenter, double-blind, placebo-controlled clinical trial in patients with pancreas divisum showed that 89% of patients who received SecreFlo were successfully administered the ECRP, compared with a 6% success rate in patients who received a placebo, the company said.

SecreFlo is currently approved by the FDA to help diagnose chronic pancreatitis and gastrinoma.

The FDA has granted SecreFlo with orphan drug designation, which means that it is the only form of secretin marketed for these indications in the United States until 2009.

[erkilein]

die Aktie trotzt dem Markt...4 $ stehen wieder zu Buche. Mal sehen, ob die 4,50 genommen werden können oder ein Doppeltop einen weiteren Anstieg verhindert.

[erkilein]

4,72 wurden erreicht, Schlusskurs 4,59- damit fängt der Run erst an; techn. Ziel sind jetzt 8 $.
Wer kann die folgenden Vorzugsrechte erklären? Im deutschen Wertpapierrecht habe ich sowas noch nicht gesehen...

Repligen Adopts Shareholder Rights Plan
Tuesday March 4, 7:50 am ET


WALTHAM, Mass., March 4 /PRNewswire-FirstCall/-- Repligen Corporation (Nasdaq: RGEN - News) today announced that on March 3, 2003 its Board of Directors adopted a shareholder rights plan under which all Common shareholders of record as of March 17, 2003 will receive rights to purchase shares of a new series of Preferred Stock. The adoption of the Rights Plan is intended as a means to guard against coercive takeover tactics and is not in response to any particular proposal.
ADVERTISEMENT


"The implementation of a shareholder rights plan will enable the Board of Directors, on behalf of its shareholders, to maximize long-term shareholder value by providing a vehicle in which the Board is actively involved in negotiating any potential takeover situations," explained Walter C. Herlihy, the Company`s President and CEO. "The time and flexibility provided by a rights plan is essential to obtaining the best potential return for shareholders."

The rights will be distributed as a non-taxable dividend and will expire ten years from the adoption date. Subject to certain exceptions, the rights will be exercisable only if a person or group acquires 15 percent or more of Repligen`s outstanding Common Stock (20 percent in the case of a Grandfathered Stockholder) or announces a tender or exchange offer upon the consummation of which such person or group would own 15 percent or more of Repligen`s outstanding Common Stock. Each right will initially entitle Common shareholders to purchase a fractional share of Preferred Stock for $50. Subject to certain exceptions, if any person or group acquires 15 percent or more of Repligen`s Common Stock, all rights holders, except the acquiring person or group, will be entitled to acquire Repligen`s Common Stock (and in certain instances the stock of the acquirer) at a discount.

The effect will be to discourage acquisitions of more than 15 percent of Repligen`s outstanding Common Stock without negotiations with the Board of Directors. The rights will trade with Repligen`s Common Stock, unless and until they are separated upon the occurrence of certain future events. Generally, Repligen`s Board of Directors may amend the Rights Plan or redeem the rights prior to 10 days (subject to extension) following a public announcement that a person or group has acquired 15 percent or more of Repligen`s outstanding Common Stock. Additional details regarding the Rights Plan will be outlined in a summary to be mailed to all shareholders following the record date.

[erkilein]

5,23...man sollte sich mal den chart über 5 Jahre anschauen...

[erkilein]

$ 6,0 haben wir schon, es wird unheimlich...

[flow_solver]

@erkilein,

ich könnt mich in den "" treten, dass ich die mal bei
3 verkauft habe, was treibt denn den Kurs im Moment so, kann man mit einer positiven Gerichtsentscheidung hoffen?

[erkilein]

der Vorstand hat mächtig Aktien gekauft, wohl eher weg. der erfolgreichen Tests zu dem Medikament gegen Autismus. Man kündigte auch Gegenmassnahmen wg. möglicher Übernahmen an, weil es für diese Krankheit bis jetzt noch kein adäquates Mittel gibt. RGEN scheint sehr von sich überzeugt zu sein. Momentan scheint aber erstmal eine Konsolidierung des Kurses angesagt.